MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Autor: Fricke SL; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Payne SN; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Favreau PF; Morgridge Institute for Research, Madison, Wisconsin., Kratz JD; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Pasch CA; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Foley TM; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Yueh AE; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Van De Hey DR; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Depke MG; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Korkos DP; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Sha GC; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., DeStefanis RA; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Clipson L; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin., Burkard ME; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Lemmon KK; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Parsons BM; Gundersen Health System, La Crosse, Wisconsin., Kenny PA; Gundersen Health System, La Crosse, Wisconsin., Matkowskyj KA; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.; William S Middleton Memorial Veterans Hospital, Madison, Wisconsin., Newton MA; Department of Statistics and Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin., Skala MC; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.; Morgridge Institute for Research, Madison, Wisconsin.; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin., Deming DA; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin. ddeming@medicine.wisc.edu.; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Feb; Vol. 18 (2), pp. 346-355. Date of Electronic Publication: 2018 Nov 13.